Affidea wins “Diagnostic Provider of the Year” at 2022 Health Investors Awards

June, 2022

Affidea, the largest European provider of advanced diagnostics, outpatient and cancer care services, is delighted to announce it has been awarded ‘Diagnostics provider of the year’ at the 2022 Health Investors Awards.

The HealthInvestor Awards recognises outstanding achievements, innovation and excellence in the independent healthcare sector and aims to reward organisations who have made a significant contribution in the medical sector.

Affidea has been praised by the judges for its innovative approach in pioneering the latest technologies to improve clinical outcomes, patients’ safety and their experience in the medical centers while at the same time driving operational efficiencies. The three innovative initiatives that placed Affidea on the spotlight at HealthInvestors Awards were:

1. The digitalisation of patients’ pathway across Affidea countries, from booking to e-registration and e-results, aiming to improve patients’ experience at every touchpoint along their medical journey.

1. The proprietary MRI Excellence program wthat offers a live view of the utilisation of the MRI units and through which Affidea achieved a 28% increase in number of exams per hour, an increase with 5% of NPS score of patients up to 81% and + 11% in revenues for the MRIs in scope. The programme focuses on driving improvements by looking at several KPIs such as the average number of exams per hour, machine idle time, opening and closing hours, number of exams, patient change and the utilisation rate at any centre. Data is extracted from over three-quarters of the 200 MRI machines across ten countries, with the aim to enhance the delivery of care and the patient experience, while driving operational efficiencies.

1. The innovative Artificial Intelligence software that Affidea installed in its PET/CT centres in Italy, Poland and Romania, to maintain the quality of the PET/CT images that have been acquired with reduced tracer dose or reduced scan time. In order to validate the AI algorithm, a pilot was carried out at Affidea IRMET center in Torino, Italy, a UEMN/EBNM and EARL accredited PET-CT site. The clinical results have been outstanding, achieving a 33% reduction in FDG dose without compromising image quality in combination with up to 50% scan time reduction. A lower dose for patients that undergo PET-CT exams translates into increased safety, while time reduction resultes in higher comfort for patients. All these have been achieved while maintaining the same image quality for an accurate diagnosis, along with operational efficiencies for the medical center.

Giuseppe Recchi, Affidea CEO, stated: “We are honoured to receive this award, on behalf of all Affidea people that contributed to this success. It is a great achievement and a recognition of the innovation mindset that drives all our initiatives at Affidea, focusing on delivering outstanding clinical excellence and state of the art patient experience. I couldn’t be prouder on behalf of all the people that work in Affidea – it is a testament that all we do at Affidea comes with great benefits to our patients, doctors and overall the health systems in every country where we are present”.

Michał Kwieciński, Senior VP Regional COO, who proudly represented Affidea at the award ceremony, stated: “It was an honour to receive the award on behalf of Affidea and our fantastic team of clinical, patient services and business professionals. We pride ourselves in providing the highest quality diagnostic imaging services across all 15 countries in which we operate. In the UK, through our Group company – Fortius clinic, we offer a unique combination of high-end diagnostics and world class orthopaedic surgery, enabling excellent clinical quality and an outstanding customer service for our patients”.

The juries that awarded Affidea for the Diagnostics Provider of the Year mentioned during the Award ceremony: The company “achieved outstanding growth through 2021 year, adding 47 new European diagnostic centres. With a strong commitment to implementing innovative clinical solutions to improve both clinical outcomes and patient safety. Affidea is strongly positioned in the national and international market place with impressive and innovative results. Affidea’s entry into the UK marks its confidence in this market, and we shall watch their progress with interest and anticipation.”

The awards ceremony was held at the Grosvenor House Hotel in London and was attended by 1,200 of the independent health sector’s key figures.

The foundation upon which Affidea has been built is trust. Both doctors and patients know that we strive to provide the best standard of care, delivered by the best professionals with the most modern technologies. Patients trust and rely on doctors. Doctors trust and rely on us.
What’s Affidea’s secret to transforming the standards of healthcare service provision? Our people. Healthcare professionals that know what they are doing and care about what they do. They make us who we are today. And who we want to be tomorrow.
We implement the highest standards and procedures to ensure safety. Affidea is committed to becoming the first European diagnostic provider to shape a new paradigm in patient safety by introducing a company wide Dose Excellence Programme ensuring the right balance between dose and image quality.
Affidea has an extensive network of international affiliations with the world’s top medical institutions to ensure that our doctors always have immediate access to the latest medical knowledge, clinical guidelines and medical procedures in all Affidea medical centres in order to ensure the highest quality diagnostics and cancer treatment.
We know that hospitality is important.  We care about how you feel and want to make each visit  to an Affidea centre as comfortable as we can.  An exceptional patient experience is ensured by delivering a personalised service in modern and comfortable service settings where you feel safe and confident that you are receiving the highest quality medical care.
We develop and exchange best practice. Patients deserve to know what we do, how we do it and why we do it. The continuous improvement of all Affidea care delivery processes is achieved by capitalising on the company’s extensive experience in 14 European countries and an organised effort to share best practice to improve patient safety and patient experience.
Technology has done more for health today than it has ever done and will do even more in the future. Affidea is committed to operating a best in class medical equipment base and maintain it’s long standing relations with major equipment producers to ensure our patients will always have access to the latest, most innovative and effective technology.